ArticleBJUI compass2021
Transition zone prostate cancer is associated with better clinical outcomes than peripheral zone cancer.
Article in BJUI compass, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Differential detection rates of clinically significant prostate cancer in transition zone versus peripheral zone lesions: Implications for transperineal magnetic resonance imaging-targeted biopsy strategy.Prostate international · 2026Article
- Analysis of the transcriptomic and metabolomic landscape of prostate cancer with different anatomical origins using snFLARE-seq and mxFRIZNGRND.Nature communications · 2026Article
- Impact of Tumor Location Within the Prostate on Prognostic Outcomes Following Radical Prostatectomy.International journal of general medicine · 2026Article
- Decoding benign prostatic hyperplasia at single-cell resolution: heterogeneity, inflammation, and beyond androgen-driven pathogenesis.Frontiers in immunology · 2026Review
- Quantifying partial pathological response rate in prostate cancer patients who underwent neoadjuvant chemotherapy using a novel morphometric approach.Journal of pathology informatics · 2025Article
- Advancing Prostate Cancer Assessment: A Biparametric MRI (T2WI and DWI/ADC)-Based Radiomic Approach to Predict Tumor-Stroma Ratio.Diagnostics (Basel, Switzerland) · 2025Article
- PTEN and ERG Biomarkers as Predictors of Biochemical Recurrence Risk in Patients Undergoing Radical Prostatectomy.Diseases (Basel, Switzerland) · 2025Article
- Gland- and cell-level heterogeneity in the prostate: A narrative review of related diseases.Current urology · 2025Article
- The differential role of IL-33 and IL-38 in prostate cancer, contradictory roles.Frontiers in immunology · 2025Review
- Characteristics of incidental prostate cancer in the United States.Prostate cancer and prostatic diseases · 2024Article
- Multiparametric-magnetic resonance imaging (mp-MRI) of the prostate and Urolift: Identifying artefact size, location and clinical implications.BJUI compass · 2024Article
- Anatomic Locations and Metastatic Risk in Prostate Cancer in African Men: Insights From an African Cohort.Cureus · 2024Article
- The Etiology and Pathogenesis of Benign Prostatic Hyperplasia: The Roles of Sex Hormones and Anatomy.Research and reports in urology · 2024Review
- Tale of two zones: investigating the clinical outcomes and research gaps in peripheral and transition zone prostate cancer through a systematic review and meta-analysis.BMJ oncology · 2024Article
- Prostate zones and tumor morphological parameters on magnetic resonance imaging for predicting the tumor-stage diagnosis of prostate cancer.Diagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- Zonal origin of prostate cancer: comparison of long-term outcomes after radical prostatectomy.International urology and nephrology · 2023Article
- Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment.Cellular & molecular biology letters · 2023Review
- Differences in the pathogenetic characteristics of prostate cancer in the transitional and peripheral zones and the possible molecular biological mechanisms.Frontiers in oncology · 2023Review
- Prostate zones and cancer: lost in transition?Nature reviews. Urology · 2022Review
- Transition zone prostate cancer is associated with better clinical outcomes than peripheral zone cancer.BJUI compass · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To determine the biological significance of zonal origins in prostate cancer. Patients and methods: Altogether, 270 consecutive radical prostatectomy cases from 2009 to 2012 were adopted. Cases were divided into those having transition zone (TZ) cancer or peripheral zone (PZ) cancer. Cases with indeterminate tumor location and central zone cancers were excluded from the analyses. Prognosis and clinicopathological features were compared between the two tumor locations. Biochemical recurrence (BCR) and clinical progression (CP) were adopted as prognostic outcome measures. Immunohistochemical features of the v-ets avian erythroblastosis virus E26 oncogene homolog (ERG)/serine peptidase inhibitor, Kazal-type 1 (SPINK1) status, and loss of phosphatase and tensin homolog (PTEN-loss), as well as conventional preoperative and postoperative characteristics, were analyzed. Results: This cohort comprised 93 cases of TZ cancer and 160 cases of PZ cancer. TZ cancer cases showed significantly higher BCR and CP-free survival rate than PZ cancer cases. Notably, no TZ cancer cases developed CP during the 7.8 years of median follow-up time. Tumor location was an independent predictive factor for BCR in the multivariate analysis. Additionally, TZ cancer cases showed a significantly lower prevalence of ERG-overexpression and PTEN-loss than PZ cancer cases (3.2% vs 20.1% and 2.2% vs 18.2%, respectively). Conclusion: TZ cancer cases showed a better prognosis and different immunohistochemical features. Conservative treatment strategies could be considered for TZ cancer cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.